Chronic Obstructive Pulmonary Disease
Conditions
Keywords
COPD
Brief summary
72 patients with mild to moderate chronic obstructive pulmonary disease were planned to be enrolled in this study and then treated with olodaterol combined with thiotropium bromide, and thiotropium bromide, respectively, for 52 weeks. To assess the effect of the test drug on small airway remodeling in patients.
Detailed description
Studies have confirmed that thiotropium bromide combined with olodaterol can significantly improve airway inflammation, quality of life and pulmonary function in patients with stable COPD, without significantly increasing adverse reactions, which is worthy of clinical promotion. At present, there are few reports on the effect of thiotropium combined with olodaterol on airway remodeling in COPD patients, so this randomized, double-blind, parallel-controlled, single-center clinical trial was designed to compare the long-term effects of thiotropium combined with olodaterol, and thiotropium on small airway remodeling in patients with mild to moderate chronic obstructive pulmonary disease. 72 patients with mild to moderate chronic obstructive pulmonary disease were planned to be enrolled in this study. After screening examination, eligible subjects were randomly assigned to the test group or the control group in a 1:1 ratio and received olodaterol combined with thiotropium bromide, and thiotropium bromide, respectively, for 52 weeks. The effect of the test drug on small airway remodeling was assessed at 12, 26, and 52 weeks after treatment.
Interventions
DRUGTiotropium Bromide Combined With Odaterol
2 puffs once daily at the same time of the day for 52 week
Sponsors
Boehringer Ingelheim
Guangzhou Institute of Respiratory Disease
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female, aged ≥ 40 years; * Meet the diagnostic criteria of COPD, and GOLD grade I - II; * FEV1/FVC \< 70% and FEV1 ≥ 50% of the expected value after the use of bronchodilators; * Patients must be able to complete all study-related steps, voluntarily participate in this study and sign the informed consen.
Exclusion criteria
* Patients with asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, pulmonary embolism, bronchiolitis obliterans, paradoxical bronchospasm; * Patients with blood eosinophilia; * Patients with upper respiratory tract infection; * Patients with liver or renal insufficiency; * Patients with severe unstable systemic diseases or malignant tumors; * Patients with glaucoma, benign prostatic hyperplasia or bladder neck obstruction; * Patients with hypokalemia, hyperglycemia, diabetes, ketoacidosis or other serious systemic diseases such as heart, brain, liver, kidney, digestive system, endocrine system, immune system, blood; * Women of childbearing age who are pregnant, lactating or plan to become pregnant; * Patients who have undergone previous pneumonectomy or received lung volume reduction surgery within 12 months before screening; * Patients with mental illness; * Patients who have participated in other clinical trials within 3 months before screening; * Allergic constitution or known allergy to atropine or its derivatives (such as isopropylamine or oxytoluium) Or those who are allergic to the intervention drugs and their ingredients; * The researchers believe that it is not appropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of Tiotropium Bromide Combined With Odaterol on endobronchial lumen area change | at week 52 | difference in change from baseline in grade 7-9 endobronchial lumen area (Ai7-9) at week 52 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect of Tiotropium Bromide Combined With Odaterol on bronchial airway wall area change | at week 52 | difference in change from baseline in grade 7-9 bronchial airway wall area (Aw and Aw% 7-9) at week 52 |
| Effect of Tiotropium Bromide Combined With Odaterol on FEV1 change | at week 52 | difference in change from baseline in trough FEV1 at week 52 |
| Effect of Tiotropium Bromide Combined With Odaterol on SGRQ total score change | at week 52 | difference in change from baseline in SGRQ （ST george's respiratory questionaire）total score at week 52 |
| Effect of Tiotropium Bromide Combined With Odaterol on mean bronchial diameter change | at week 52 | difference in change from baseline in grade 7-9 mean bronchial diameter (Dmean7-9) at week 52 |
| Effect of Tiotropium Bromide Combined With Odaterol on peripheral airway resistance change | at week 52 | difference in change from baseline in peripheral airway resistance (R5-R20) at week 52 |
| Effect of Tiotropium Bromide Combined With Odaterol on CAT total score change | at week 52 | difference in change from baseline in CAT（Chronic obstructive pulmonary disease assessment test） total score at week 52 |
| Effect of Tiotropium Bromide Combined With Odaterol on mMRC total score change | at week 52 | difference in change from baseline in mMRC（Modified British medical research council） total score at week 52 |
| Effect of Tiotropium Bromide Combined With Odaterol on resonance frequency change | at week 52 | difference in change from baseline in resonance frequency (Fres) at week 52 |
Countries
China
Contacts
Primary ContactShiyue Li, Doctor
Backup ContactZiqing Zhou, Doctor
Outcome results
None listed